Navidea Biopharmaceuticals, Inc.
NAVB
$0.0001
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -- | 301.09% | 50.58% | 4.64% | -134.14% |
| Total Depreciation and Amortization | -- | 24.31% | 20.52% | 24.41% | 36.46% |
| Total Amortization of Deferred Charges | -- | 87.19% | -- | -- | -- |
| Total Other Non-Cash Items | -- | 75.38% | -445.71% | -9.84% | -43.63% |
| Change in Net Operating Assets | -- | -337.01% | 911.02% | 10.41% | 1,549.12% |
| Cash from Operations | -- | 319.25% | 32.63% | 10.82% | 7.67% |
| Capital Expenditure | -- | 100.00% | 64.05% | 100.00% | 20.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 43.02% | 68.11% | 15.29% | 44.01% |
| Cash from Investing | -- | 46.37% | 66.67% | 19.46% | 40.77% |
| Total Debt Issued | -- | -80.00% | -- | -- | -- |
| Total Debt Repaid | -- | -342.54% | 40.94% | 42.39% | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 179.61% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -273.97% | -- | -- | -- |
| Cash from Financing | -- | 8.25% | 40.94% | 21.73% | 181.27% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | 787.22% | 34.90% | 11.56% | 6,780.52% |
